Furthermore, the melanoma antigen gp100 has emerged as a pivotal factor in directing in vivo tumor rejection responses via immune reactions facilitated by tumor-infiltrating lymphocytes (TILs) in individuals with melanoma 34. This evidence concerns the gene PMEL and neoplasm.